Theratechnologies Inc. Price & Performance (THTX)

IMAC Holdings, parent company of Theralink Technologies, executed a promissory note for $36,050 on April 2, 2025, with a purchase price of $25,750. The unsecured note matures December 24, 2025, and can be prepaid without penalty. This move signals IMAC’s ongoing efforts to secure operational funding.12

Faith Zaslavsky, previously President and COO, has taken the helm as President and CEO of Theralink Technologies. This leadership transition follows the company’s integration into IMAC Holdings and reflects a broader push toward commercialization and operational efficiency in precision oncology diagnostics.34

Theralink Technologies has expanded its patent holdings to ten, securing exclusive rights to a Vanderbilt University patent for predicting immunotherapy responses. This acquisition enhances Theralink’s capabilities in developing companion diagnostics, aiming to improve patient outcomes in breast and other solid tumors.5